Respiratory depression

Respiratory depression is a slowing and shallowing of the breath caused by direct suppression of the central nervous system's respiratory drive.

As a drug effect it is acute and dose-proportional, resolving as the substance wears off. It ranges from a subtle heaviness in the chest and a slowed breathing rate to near-complete cessation — a state that is rapidly fatal.

It is uncommon but among the most serious adverse effects any psychoactive substance can produce. It is most commonly induced at high doses under opioids such as heroin, fentanyl, and codeine, and under depressants such as alcohol, alprazolam, and GHB. It also appears at high doses under dissociatives such as dextromethorphan and 3-HO-PCE, and under deliriants such as diphenhydramine and datura.

Respiratory depression is felt as a heaviness in the chest and a fading of the ordinary urge to breathe: breaths come slower, shallower, and farther apart, and the effort that normally drives inhalation quietly recedes.

It commonly comes with a drowsy, lead-limbed weight across the body, skin that is cool and clammy, and a bluish cast at the lips and fingertips in severe cases. Attending to the breathing often reveals how far it has slowed. At higher doses, particularly under opioids, the drive to stay conscious erodes alongside the drive to breathe.

Respiratory depression arises through different pathways depending on the drug class:

• Opioids — bind mu-opioid receptors in brainstem respiratory centers, directly reducing those centers' sensitivity to rising carbon dioxide and suppressing the drive to breathe.
• Depressants — potentiate GABA-A receptor activity, broadly dampening central nervous system function including the brainstem circuits that sustain rhythmic breathing.
• Dissociatives — act primarily as NMDA receptor antagonists; respiratory effects are less pronounced but can emerge at high doses.
• Deliriants — anticholinergic action can impair airway reflexes and depress the respiratory drive at toxic doses.

How much each pathway contributes in a given case is not fully understood.

Who experiences it, and how severely, varies widely. Dose is the primary driver — risk rises sharply at high doses and is dramatically elevated when opioids are combined with depressants such as alcohol, alprazolam, or GHB.

Tolerance to opioids reduces risk at a given dose, but that tolerance is lost quickly after a period of abstinence, making a return to prior doses especially dangerous. Underlying respiratory illness and low body weight raise baseline vulnerability.

Using alongside a trusted person who can recognize and respond to the signs reduces the chance of a fatal outcome.